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ABSTRACT 
Synthetic 3-hydroxyflavone analogues (JY-1, JY-2, JY-3, JY-4), were tested for antidiabetic 
activity in high-fructose-diet-fed (66 %, for 6 weeks) insulin-resistant Wistar rats (FD-fed 
rats). The fasting blood glucose, insulin, creatinine and AGEs were decreased to near normal 
upon treatment with test compounds. Insulin resistance markers such as HOMA-IR, K-ITT, 
plasma triglycerides, lipids, endogenous antioxidant defense and glycogen were restored in 
FD-fed rats after treatment with 3-hydroxyflavones. It is known that insulin resistance is part-
ly because of oxidative stress and hence antioxidant activity was determined. They exhibited 
significant in vitro DPPH and ABTS radical scavenging activity (IC50: 10.66-66.63 µM). Test 
compounds inhibited ROS and NO production in RAW 264.7 cells (IC50: 10.39–42.63 µM) 
and they were found as potent as quercetin. Further, the test compounds inhibited lipid perox-
idation at low concentrations (IC50: 99.61-217.47 µM). All test compounds at concentrations 
100-200 µM protected calf thymus DNA-damage by Fenton reaction. In addition, test com-
pounds inhibited protein glycation in different in vitro antiglycation assays. JY-2 showed 
maximum potency in all the stages of glycation which was comparable to the standard querce-
tin and aminoguanidine. Test compounds also enhanced the glucose uptake by L6 myotubes 
at an EC50 much lower than that of quercetin. Thus the synthetic 3-hydroxyflavones were 
found to have good antidiabetic activity by pleotropic and multimodal suppression of insulin 
resistance and enhancement of glucose uptake by skeletal muscles. These compounds are 
non-toxic at the doses tested. Further, the combined antioxidant and antiglycation activities of 
these molecules have complementary benefits in management of diabetes. 
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INTRODUCTION 
Flavonoids are widely distributed in 
plants and identified as potential leads in an-
tidiabetic drug discovery (Mukherjee et al., 
2006). Flavonoids exhibit antidiabetic action 
by multimodal mechanisms and also influ-
ence the pleiotropic mechanisms involved in 
insulin signaling (Cazarolli et al., 2008). 
Flavonoids, owing to their potent antioxidant 
activity, can strongly inhibit the formation of 
glycosylation end products (AGEs) and also 
counteract the contribution of oxidative 
stress to disease progression (Wu and Yen, 
2005). 
Oxidative stress is one of the major caus-
es for disease burden in diabetes and related 
metabolic disorders and antioxidant supple-
mentation is proven to be beneficial (Houstis 
et al., 2006; Rahimi et al., 2005). Reactive 
oxygen species (ROS) and reactive nitrogen 
species (RNS) cause DNA damage and per-
oxidation of membrane lipids. Superoxide 
(O2•-) radicals generated during glucose-
oxidation reacts with nitric oxide (NO) re-
leased by endothelium and macrophages 
forming highly reactive peroxynitrite radical 
(ONOO-), and eventually aggravating the 
inflammatory responses leading to diabetic 
micro and macrovascular complications 
(Son, 2012). 
In diabetes, increased free radical genera-
tion leads to protein cross-linking, protein 
glycosylation and generation of AGEs. In-
creased ROS and reactive carbonyl species 
(RCS) such as 3-deoxyglucosone, glyoxal, 
and methylglyoxal (MGO), are critical in-
termediates formed during protein glycation. 
The end product of Amadori rearrangement 
in aldemine linkage between glucose and 
protein is called fructosamine (1-amino-1-
deoxyfructose/isoglucosamine). All the 
above mentioned intermediates are identified 
as the important precursors of AGEs in dia-
betes (Goldin et al., 2006). Further, AGEs 
can bind to cell membrane receptor called 
RAGE (receptor for AGEs) and mediate the 
release of a series of inflammatory mediators 
and growth factors. Reports suggest that 
AGE-RAGE is the predominant mechanism 
in pathogenesis of nephropathy and retinopa-
thy (Ramasamy et al., 2011). Hence, antidia-
betic molecules with antioxidant and anti-
glycation activity will have additional bene-
fits over currently available antidiabetic 
drugs. 
Quercetin, one among the most potent 
flavonoids from natural sources studied for 
antidiabetic activity, acts by multiple mecha-
nisms and has a potential to emerge as a 
nutraceutical (Boots et al., 2008). Our lab 
previously reported that the plant extract 
Dodonaea viscosa (Family: Sapindaceae) 
areolar parts showed antidiabetic activity in 
high-fat low-dose streptozotocin (STZ) rats 
(Veerapur et al., 2010a) and in high-fructose 
induced insulin resistance in rats (Veerapur 
et al., 2010b). The major constituent respon-
sible for the antidiabetic activity of the plant 
extract, Dodonaea viscosa was a flavonoid, 
quercetin. 
Though, plant flavonoids are available in 
plenty, isolation and purification is a major 
hurdle (Havsteen, 2002). Further, structural 
diversity of the flavonoid nucleus offers 
scope to generate synthetic derivatives with 
enhanced biological activity and bioavaila-
bility. In view of these, we synthesized few 
3-hydroxflavone analogues by standard pro-
cedure (Jayashree et al., 2010) and selected 
four promising analogues (namely, JY-1, JY-
2, JY-3 and JY-4; Figure 1), for evaluation 
of their antidiabetic activity. 
 
Figure 1: Structures of 3-hydroxyflavone analogues 
 
 
MATERIALS AND METHODS 
Drugs and chemicals 
2,2'-diphenyl-1-picrylhydrazyl (DPPH), 
2,2-azinobis (3-ethylbenzothiazoline-6-sul-
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phonic acid) (ABTS), 2,4,6-Tris(2-pyridyl)-
s-triazine (TPTZ), calf thymus DNA, querce-
tin, deoxy-D-ribose, thiobarbituric acid 
(TBA), Tris-Acetate-EDTA (TAE) buffer, 
agarose gel, MGO, aminoguanidine hemisul-
fate (AG), Trypan blue, lipopolysaccharide 
(LPS) from E. coli serotype 0111:B4, 2',7'-
dichlorodihydrofluor-escin diacetate (DCFH-
DA), NG-nitro-L-arginine methyl ester (L-
NAME), diphenylene iodonium (DPI), Dul-
beccos’ Modified Eagle Medium (DMEM) 
for cell culture, bovine serum albumin 
(BSA) 5,5'-dithio-bis-2-nitrobenzoic acid 
(DTNB, Ellman’s reagent), 1-chloro-2,4-
dinitrobenzene (CDNB), reduced glutathione 
(GSH) and superoxide dismutase (SOD) 
were purchased from Sigma-Aldrich, USA. 
Fetal Calf Serum was purchased from Invi-
trogen, USA. Gentamicin was purchased 
from Abbott Healthcare Pvt. Ltd, Mumbai, 
India. Carboxymethyl cellulose (CMC), 
haemoglobin, nitroblue tetrazolium (NBT), 
fructose, anthrone and oyster-glycogen were 
purchased from Himedia, Mumbai. Pioglita-
zone was a gift from Hetero Drugs, Hydera-
bad, India. Other reagents were purchased 
from standard chemical suppliers. The test 
compounds, quercetin and pioglitazone were 
suspended in 0.5 % CMC before administra-
tion to the animals. 
 
Animals 
Male Wistar rats (7 to 8 week; 150–
180 g), maintained in sanitized polypropyl-
ene cages (3 per cage) in air conditioned 
rooms (23±2°C, 35–60 % humidity with 12 
light–dark cycle) were obtained from the 
central animal facilities of Manipal Universi-
ty. The rats were fed with standard rat pellet 
diet (Hindustan Lever Ltd., Mumbai, India) 
and water ad libitum. Prior approval was ob-
tained from the Institutional Animal Ethical 
Committee (IAEC) (letter No. IAEC/KMC/ 
06/2006–2007) and the experiments were 
conducted according to the guidelines of 
Committee for the Purpose of Control and 
Supervision of Experiments on Animals 
(CPCSEA), India. 
 
Acute oral toxicity and dose optimization 
study of 3-hydroxyflavone analogues 
Acute oral toxicity study was carried out 
as per the OECD guidelines TG-425. As fla-
vonoids are known antioxidants with biolog-
ical activity, we chose test compounds for a 
detailed antioxidant activity using the antiox-
idant biomarker ferric reducing ability of 
plasma (FRAP). Results were used to cali-
brate and optimize the dose (Benzie and 
Strain, 1996). Five male Wistar rats weigh-
ing 150-180 g, in each group were adminis-
tered 10, 20, 40, 80 and 160 mg/kg/day, p.o., 
doses of synthesized test compounds for sev-
en days. On the last day, 2 h after ingestion 
of test compounds, blood was collected by 
retro-orbital veni-puncture and the plasma 
separated to determine FRAP by the standard 
procedure using TPTZ-reagent. The FRAP 
values were obtained in triplicate and ex-
pressed as millimoles of ferric ions reduced 
to ferrous ions per ml of plasma. Control 
(treated with vehicle) and quercetin-treated 
(10 mg/kg/p.o./day) animals were used for 
comparison. In continuation of the toxicity 
studies, a sub-acute tolerance test for 28 days 
was carried with the optimum dose in order 
to examine untoward effects of test com-
pounds. 
 
Antidiabetic activity of 3-hydroxyflavone 
analogues 
Induction of insulin resistance by high 
fructose diet (FD) and treatment protocol: 
Wistar rats were made insulin resistant by 
feeding high-fructose diet (FD) for 6 weeks 
(42 days). The FD was prepared by mixing 
66 % fructose with the normal pellet powder 
(Veerapur et al., 2010b). The experimental 
rats were divided into 8 groups (n=6) and 
they were treated orally as follows 
G1: Normal pellet diet (NPD) + 0.5 % CMC 
(2 ml/kg) 
G2: FD + 0.5 % CMC (2 ml/kg) 
G3: FD + Piolglitazone (10 mg/kg) 
G4: FD + Quercetin (10 mg/kg) 
G5: FD + JY-1 (80 mg/kg) 
G6: FD + JY-2 (80 mg/kg) 
G7: FD + JY-3 (80 mg/kg) 
G8: FD + JY-4 (80 mg/kg) 
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Male rats were used because females 
have been shown to be protected from chan-
ges in fructose-induced hyperinsulinemia 
and insulin resistance (Galipeau et al., 2002). 
 
Effects of test compounds on FD-fed  
insulin resistant rats 
Food intake and body weight monitoring: 
High-fructose diet (FD) was freshly prepared 
daily and rats (3 per cage) were provided 
with approximately 80 g fresh feed per cage, 
between 9.00–11.00 am daily. Approximate-
ly 20–25 g feed remained on the next day. 
The same quantity of feed was provided at 
the same time throughout the study period. 
In order to reduce the amount of left-over 
feed and to eliminate spillage, the quantity of 
feed provided daily was only slightly more 
than what was consumed each day. Total 
consumption was estimated from the differ-
ence in the weight of feed added each day 
and then subtracting the weight of the feed 
left-over after 24 h consumption on Mon-
days, Wednesdays, and Fridays. Three val-
ues obtained for each week were averaged to 
provide an index of daily consumption for 
the week. Data were not included whenever 
excessive spillage was observed. Cumulative 
food intake was calculated by multiplying 
average daily food intake by 7, then sum-
ming the calculated weekly averages 
throughout the treatment period. The cumu-
lative food intake was calculated per 100 g 
body weight of animal. 
The body weights of each rat in respec-
tive groups were recorded each week during 
the treatment period. The initial body weight 
before start of FD-feeding was considered as 
the basal weight of the rat. At the end of the 
study, body weights of the treated groups 
(G3 to G8) were compared with induced 
group (G2) and the normal control group 
(G1). 
Fasting blood glucose and oral glucose 
tolerance test: On 42nd day, the 12 fasted rats 
were administered glucose (2 g/kg, p.o.) and 
blood samples were collected from the cau-
dal vein by means of a small incision at the 
end of the tail at 0 min (immediately after 
glucose load), 15, 30, 60, 90 and 120 min 
after glucose administration. Blood glucose 
was estimated by glucose oxidase strips us-
ing a glucometer (Accu-chek® Active, Roche 
diagnostics). The results are expressed as 
integrated area under curve for glucose, us-
ing GraphPad Prism software. 
Estimation of serum lipid profiles: Serum 
triglyceride (TG), total cholesterol (TC) and 
high density lipoprotein (HDL) were esti-
mated by semi-autoanalyser, Star 21 (Seac 
Radim group) using diagnostic reagent kit 
(Aspen Laboratories, Delhi). Very low den-
sity lipoprotein (VLDL) and low density li-
poprotein (LDL) were calculated by the fol-
lowing formulae (Veerapur et al., 2010b). 
VLDL = (TG) /5; LDL = TC – VLDL – HDL 
TC/HDL ratio was calculated as a marker of 
dyslipidemia 
Estimation of serum insulin and homeo-
static model assessment (HOMA-IR): Serum 
insulin was estimated by radioimmunoassay 
using an immunoassay kit. The insulin re-
sistance index was assessed by HOMA-IR, 
calculated by the following formula 
(Veerapur et al., 2010b): 
HOMA-IR = [fasting plasma glucose (mg/dl) x 
fasting plasma insulin (μ IU/ml)] /405 
Determination of insulin tolerance test: 
Insulin tolerance test was carried out by in-
traperitoneal injection of insulin bolus 
(4 IU/kg; Actrapid®, Novo-Nordisk). Blood 
glucose was determined immediately before 
and 5, 10, 15, 30, 60, 90, and 120 min after 
the injection. The first-order rate constant for 
the disappearance rate of glucose from plas-
ma (K-ITT) was estimated from the slope of 
the regression line of log plot of the blood 
glucose against time (Akinmokun et al., 
1992). 
Estimation of serum AGEs and creati-
nine: The serum AGEs was determined by 
previously reported specific fluorescence 
assay (Yanagisawa et al., 1998). Serum cre-
atinine was determined by the modified 
Jaffe’s method using commercially available 
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kit (Aspen Laboratories, Delhi) with an auto-
analyzer (Star 21, Seac Radim Group). 
Biochemical parameters from rat liver 
homogenate: After OGTT, the rats were sac-
rificed by cervical dislocation and liver was 
perfused with saline, dissected out, and a 
10 % liver homogenate was prepared with 
ice-cold saline-EDTA using Teflon-glass 
homogenizer (Yamato LSG LH-21, Japan). 
The homogenate was centrifuged at 10,000 
rpm for 10 min (at 4-8 °C) using cooling 
centrifuge (MIKRO 220R, Hettick Lab, 
Germany). The pellet was discarded and su-
pernatant obtained was used for the estima-
tion of oxidative stress markers in the ho-
mogenate. The enzymatic antioxidants such 
as glutathione-S-transferase (GST), catalase 
and SOD were determined by standard 
methods. Similarly non-enzymatic antioxi-
dants such as TBA-reactive substances 
(TBARS), GSH and total thiols were esti-
mated by standard colourimetric assays 
(Veerapur et al., 2010b). The total protein 
was determined by Lowry’s method. The 
concentration of antioxidant enzymes was 
expressed in terms of protein content in the 
liver homogenate. Liver glycogen was esti-
mated by the standard method using an-
throne reagent (van der Vies, 1954). The gly-
cogen content in liver was expressed in mg/g 
wet weight. 
Glucose uptake from isolated hemi-
diaphragm of insulin resistant rats: The 
hemi-diaphragms were isolated from the FD-
rats and glucose uptake was studied in the 
presence and absence of insulin (Veerapur et 
al., 2010a). 
 
Antioxidant and antiglycation activity of 
3-hydroxyflavone analogues 
Free radical-scavenging activities of test 
compounds were measured in terms of hy-
drogen donating or radical-scavenging abil-
ity using the stable radicals such as, DPPH 
and ABTS. The hydroxyl radical (•OH) 
scavenging, inhibition of lipid peroxidation 
and calf thymus DNA protection by test 
compounds were carried out as per the 
standard methods (Prabhakar et al., 2006). 
Quercetin was used as standard. The antioxi-
dant activity of the test compounds was also 
assessed by their ability to inhibit LPS-
induced ROS and NO-production in RAW 
264.7 cells (Mathew et al., 2013). L-NAME 
was used as standard for NO-inhibition assay 
and DPI in intracellular ROS inhibition as-
say. 
The compounds were tested for their an-
tiglycation properties by hemoglobin-glu-
cose assay (Somani et al., 1989), BSA-MGO 
assay and BSA-glucose assay (Bhavesh et 
al., 2013). Further, antiglycation activity was 
also determined by fructosamine assay 
(Sharma et al., 2002). 
 
Glucose uptake from L6 myotubes 
L6 rat skeletal muscle cell-line was pur-
chased from National Centre for Cell Sci-
ences (NCCS), Pune. 2500 cells/well in 
complete DMEM media were seeded in a 
96-well black plate and incubated at 37 °C, 
5 % CO2. After 24 h , the wells were replaced 
with sterile HBSS without glucose for 5 h, 
followed by incubation with test compounds 
(10-200 µM)/vehicle (untreated control) in 
sterile PBS for 1 h. Insulin (100 nM), used as 
the standard, was incubated for 10 min. The 
cells were exposed to 2-NBDG (100 µM) for 
5 min and the fluorescence intensity was 
measured, after replacing the wells with 
PBS, using a spectrofluorimeter. 2-NBDG is 
a fluorescent D-glucose derivative chemical-
ly, 2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl) 
amino]-2-deoxy-D-glucose with λex/em = 465/ 
540 nm (Zou et al., 2005). The percentage 
increase in basal glucose uptake with respect 
to untreated control was calculated and 50 % 
effective concentration (EC50) was deter-
mined graphically. 
 
Statistical analysis 
Comparison of mean ± SEM values be-
tween various groups was performed by one-
way ANOVA followed by Tukey post-test. 
Data analysis was carried out with the help 
of GraphPad prism Software, version 5.00 
(San Diego, CA, USA). Treatment groups 
were compared to induced control (FD-rats) 
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and normal control (NPD-rats). P < 0.05 was 
considered as statistically significant.  
 
RESULTS 
Acute oral toxicity and dose optimization of 
3-hydroxyflavone analogues  
The test compounds at doses 2 g/kg, p.o., 
did not produce any mortality in rats within 
72 h. No detectable symptoms of toxicity to 
central nervous system and autonomic nerv-
ous system were noted. FRAP was reported 
to be a reliable biomarker of antioxidant ac-
tivity for flavonoids and flavonoid-rich fruits 
(Lotito and Frei, 2006). We applied this as-
say for optimizing the dose for antidiabetic 
activity. There was a graded increase in 
FRAP upon treatment with the test com-
pounds, which peaked at 80 mg/kg/day, p.o., 
for all the test compounds (Figure 2). After 
seven days of treatment, test compounds at 
80 mg/kg, were found to be comparable in 
efficacy to quercetin at 10 mg/kg/day. Above 
80 mg/kg, the activity did not increase with 
higher doses. Hence the dose of all test com-
pounds was optimized to 80 mg/kg/day, p.o., 
for the rest of the study.  
The test compounds upon treatment for 
28 days with the optimized dose did not 
show any untoward effects, when observed 
both for CNS and ANS related symptoms. 
There were no observable changes in the 
hematological parameters and none of the 
compounds had any significant effects on 
fasting blood glucose and lipid profile. 
 
 
 
Figure 2: FRAP values for dose optimization of test compounds in Wistar rats 
Ferric reducing power of plasma (FRAP) was expressed in mmol of ferric reduced to ferrous form per ml of plas-
ma (Values are expressed in mean ± SEM; n=5). [A], [B], [C] and [D] represents compounds JY-1, JY-2, JY-3 and 
JY-4 respectively; (*: p < 0.05 compared to day 0, in each group; values are mean ± SEM; n=5). 
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High-fructose diet induced diabetes and  
insulin resistance in Wistar rats 
Food intake and body weight: The high-
fructose (66 % w/w x 42 days) increased the 
body weight significantly (1.25 fold) com-
pared to NPD-rats (Figure 3A). Increase in 
body weight was correlated to cumulative 
increase in food intake (Figure 3B). Body 
weights were significantly lower in treated 
group compared to the FD-rats. In multiple 
comparisons with pioglitazone, quercetin, 
JY-2 and JY-1, there was no significant dif-
ference in body weights and food intake, in-
dicating JY-2 has highest activity in lower-
ing the body weight and food intake, among 
the four compounds selected followed by 
JY-1. 
Induction of insulin resistance in rats: In 
FD-rats there was significant increase in fast-
ing glucose levels compared to NPD-rats 
(142.3 ± 11.4 vs 93.2 ± 9.4 mg/dl of NPD-
rats). NPD-fed rats (G1) did not produce sig-
nificant changes in blood glucose upon chal-
lenge with glucose (2 g/kg). But, there was 
significant impairment in tolerance to exo-
genously administered glucose in FD-fed 
rats compared to NPD-rats (Figure 4). The 
AUC was significantly increased for FD-rats 
compared to NPD-rats (Figure 4). Also, 
HOMA-IR (33.87 ± 5.1 in FD vs 7.35 ± 3.08 
in NPD) calculated from the serum insulin 
levels (97.24 ± 10.4 vs 31.9 ±7.9 μIU/ml) 
were increased significantly (Figure 5). 
These parameters confirmed the induction of 
insulin resistance in FD-fed rats. 
 
Effect of 3-hydroxyflavone analogues in 
FD-rats 
Fasting blood glucose and OGTT: Upon 
treatment with test compounds, FBG were 
significantly lowered. Reduction was most 
significant with JY-2 and JY-1. AUC for the 
120 min interval was not altered significantly 
for all test compounds selected. The AUC 
for JY-2 was significantly lower than that of 
FD-rats and was most potent among the se-
lected compounds (p > 0.05) and efficacy 
was comparable to that of quercetin and 
pioglitazone (Figure 4). 
  
 
 
 
Figure 3: 3-Hydroxyflavones on body weight and cumulative food intake in FD-fed rats 
A: Body weight (g); B: Cumulative food intake; G1: Normal control; G2: FD-fed diabetic control; G3: Diabetic + 
pioglitazone (10 mg/kg/day, p.o.); G4: Diabetic + Quercetin (10 mg/kg/day, p.o.); G5: Diabetic + JY-1; G6: Diabet-
ic + JY-2; G7: Diabetic + JY-3; G8: Diabetic + JY-4; (test compounds at optimized dose 80 mg/kg/day, p.o.);  
#: p < 0.05 treatment groups are compared to normal rats (G1); *: p < 0.05 treatment groups are compared to in-
duced group (G2). 
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Figure 4: Effect of 3-hydroxyflavones on fasting blood glucose and OGTT in FD-fed rats 
A: Fasting blood glucose (FBG) mg/dl; B: OGTT; C: Area under the curve [AUC]; G1: Normal control; G2: FD-fed 
diabetic control; G3: Diabetic + pioglitazone (10 mg/kg/day, p.o.); G4: Diabetic + Quercetin (10 mg/kg/day, p.o.); 
G5: Diabetic + JY-1; G6: Diabetic + JY-2; G7: Diabetic + JY-3; G8: Diabetic + JY-4; (test compounds at optimized 
dose 80 mg/kg/day, p.o.); a: p < 0.05 treatment groups are compared to normal control (G1); b: p < 0.05 treatment 
groups are compared to FD-fed diabetic control group (G2). 
 
Figure 5: Effect of 3-hydroxyflavones on serum insulin, HOMA-IR and insulin tolerance in FD-fed rats 
A: Fasting serum insulin (μIU/ml); B: HOMA-IR: Defined as homeostatic model assessment of insulin resistance 
and calculated by the formula HOMA-IR = [fasting plasma glucose (mg/dl) x fasting plasma insulin (μIU/ml)]/405; 
C: K-ITT: Defined as first-order rate constant for the disappearance rate of glucose from plasma was estimated 
from the slope of the regression line of the log plot of blood glucose against time; G1: Normal control; G2: FD-fed 
diabetic control; G3: Diabetic + pioglitazone (10 mg/kg/day, p.o.); G4: Diabetic + Quercetin (10 mg/kg/day, p.o.); 
G5: Diabetic + JY-1; G6: Diabetic + JY-2; G7: Diabetic + JY-3; G8: Diabetic + JY-4; (test compounds at optimized 
dose 80 mg/kg/day, p.o.); a: p < 0.05 treatment groups are compared to normal control (G1); b: p < 0.05 treatment 
groups are compared to FD-fed diabetic control group (G2). 
 
Fasting insulin, HOMA-IR, K-ITT val-
ues: Fasting insulin level of FD-rats was sig-
nificantly higher than that of NPD-rats 
(97.24 ± 10.41 vs 31.93 ± 7.58 μIU/ml in 
NPD; Figure 5A). The degree of insulin re-
sistance calculated by HOMA-IR was signif-
icantly higher in FD-rats than controls (33.87 
± 5.10 vs 7.35 ± 3.08 of NPD; Figure 5B). 
The test compounds, pioglitazone and quer-
cetin when administered to FD-rats, resulted 
in significantly reduced serum insulin levels. 
Similarly the HOMA-IR values decreased 
significantly. JY-2 was found to be the most 
effective in reducing FD-induced insulin re-
sistance. 
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Glucose clearance on administration of 
insulin (4 IU/kg, i.p.) was rapid in the NPD-
rats compared to FD-rats, confirming diet-
induced insulin resistance (Figure 5C). Insu-
lin-induced plasma glucose decay rate con-
stant (K-ITT) was significantly lower for the 
NPD-rats compared to FD-rats (0.004 ± 
0.0009 vs 0.0015 ± 0.0005 mg/dl/min). JY-2, 
JY-1 and quercetin were apparently more 
beneficial than pioglitazone in insulin-
induced plasma glucose decay. 
Serum AGEs and creatinine: The serum 
AGEs levels were determined by measuring 
the relative fluorescence in arbitrary units 
(AU). There was significant increase in AG-
Es (≈8 folds) in FD-rats compared to the 
NPD-rats (10.22 ± 1.02 vs 1.32 ± 0.53 AU; 
Figure 6A). Serum AGEs levels were signif-
icantly brought down by treatment with test 
compounds, quercetin and pioglitazone. Fur-
ther, the increase in AGEs was associated 
with a proportionate increase in the serum 
creatinine levels (Figure 6B). FD feeding 
increased serum creatinine significantly 
when compared to the NPD-rats (2.03 ± 0.07 
vs 0.58 ± 0.05 mg/dl in NPD-rats). Likewise, 
there was a significant decrease in the ele-
vated serum creatinine levels upon treatment 
with test compounds. JY-2 treatment was 
most effective in lowering creatinine levels 
among the selected compounds. 
Lipid parameters: The serum TG, TC, 
LDL and VLDL values were significantly 
increased and HDL, was significantly de-
creased in FD-rats, when compared to NPD-
rats (TG = 214.6 ± 15.1 vs 102.25 ± 8.6; TC 
= 150.68 ± 11.8 vs 84.23 ± 12.7; LDL= 
93.57 ± 10.70 vs 22.55 ± 5.8; VLDL = 42.60 
± 3.2 vs 20.42 ± 4.5; HDL = 14.2 ± 4.62 vs 
41.42 ± 2.1; Figure 7). Thus, there was sig-
nificant dyslipidemia in FD-rats. The TC/ 
HDL ratio, a marker of dyslipidemia, was 
significantly increased in FD-rats compared 
to the NPD-rats (10.65 ± 1.6 vs 2.04 ± 0.94). 
Treatment with test compounds, pioglitazone 
and quercetin significantly normalized both 
serum lipid levels and TC/HDL ratio. JY-1 
and JY-2 treatment significantly lowered 
dyslipidemia marker TC/HDL to 4.85 ± 1.16 
and 4.02 ± 0.97, as opposed to 10.60 ± 1.52 
in FD). Correction of dyslipidemia is the 
most significant outcome of JY-2 and JY-1 
treatment, which was found to be compara-
ble to quercetin and pioglitazone. 
 
 
Figure 6: Effect of 3-hydroxyflavones on serum AGEs and creatinine in FD-fed rats 
A: Serum advanced glycosylation end products (AGEs) measured as arbitrary units (AU); B: Serum creatinine 
(mg/dl); G1: Normal control; G2: FD-fed diabetic control; G3: Diabetic + pioglitazone (10 mg/kg/day, p.o.); G4: 
Diabetic + Quercetin (10 mg/kg/day, p.o.); G5: Diabetic + JY-1; G6: Diabetic + JY-2; G7: Diabetic + JY-3; G8: 
Diabetic + JY-4; (test compounds at optimized dose 80 mg/kg/day, p.o.); a: p < 0.05 treatment groups are com-
pared to normal control (G1); b: p < 0.05 treatment groups are compared to FD-fed diabetic control group (G2). 
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Figure 7: Effect of 3-hydroxyflavones on serum lipid profile in FD-fed rats 
A: TG: Triglycerides; B: TC: Total cholesterol; C: HDL: High density lipoprotein; D: LDL: Low density lipoprotein; 
E: VLDL: Very low density lipoprotein; F: TC/ DHL–ratio; G1: Normal control; G2: FD-fed diabetic control; G3: 
Diabetic + pioglitazone (10 mg/kg/day, p.o.); G4: Diabetic + Quercetin (10 mg/kg/day, p.o.); G5: Diabetic + JY-1; 
G6: Diabetic + JY-2; G7: Diabetic + JY-3; G8: Diabetic + JY-4; (test compounds at optimized dose 80 mg/kg/day, 
p.o.); All values mean ± SEM (n=6); a: p < 0.05 treatment groups are compared to normal control (G1); b: p < 0.05 
when treatment groups are compared to induced group (G2). 
 
Endogenous antioxidant and glycogen in 
liver 
GSH: NPD-rats had basal GSH level of 
25.68±3.99 nmol/mg of protein. Fructose 
feeding for 6 weeks significantly reduced 
GSH levels (8.1±3.69 nmol/mg of protein). 
Treatment with test compounds was effec-
tive in increasing GSH levels in FD-rats. 
Similarly, quercetin and pioglitazone signifi-
cantly restored GSH levels (Figure 8A). 
Total thiols: FD-rats showed significant-
ly decreased total thiol levels compared to 
NPD-rats (2.52 ± 2.03 vs 12.87 ± 2.9 µmol/ 
mg of protein). Treatment with test com-
pounds restored thiols significantly com-
pared to the FD-rats. The standard flavonoid, 
quercetin and pioglitazone also restored the 
total thiols significantly compared to FD-rats 
(Figure 8B). 
TBARS: FD-feeding increased TBARS 
levels by approximately three folds (48.6 ± 
9.1 nmol/g in NPD vs 145.2 ± 14.7 nmol/g in 
FD (Figure 8C). Treatment with test com-
pounds significantly lowered the TBARS 
levels compared to FD-rats. Standard flavo-
noid quercetin and pioglitazone significantly
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Figure 8: Effect of 3-hydroxyflavones on enzymatic, non-enzymatic antioxidants and TBARS in liver of 
FD-fed rats 
A: GSH (nmol/ mg proteins); B: Total thiols (μmol/ mg protein); C: TBARS nmol/ g of tissue; D: SOD U/mg pro-
tein; E: Catalase (U/mg proteins); F: GST U/mg proteins; G1: Normal control; G2: FD-fed diabetic control; G3: 
Diabetic + pioglitazone (10 mg/kg/day, p.o.); G4: Diabetic + Quercetin (10 mg/kg/day, p.o.); G5: Diabetic + JY-1; 
G6: Diabetic + JY-2; G7: Diabetic + JY-3; G8: Diabetic + JY-4; (test compounds at optimized dose 80 mg/kg/day, 
p.o.); All values mean ± SEM (n=6); a: p < 0.05 treatment groups are compared to normal control (G1); b: p < 0.05 
when treatment groups are compared to induced group (G2). 
 
 
normalized the levels of TBARS indicating 
significant protection from lipid peroxidation 
in liver. 
SOD: FD-rats significantly reduced SOD 
by about 4.5 folds (6.75 ± 4.49 vs 32.07 ± 
2.39 U/mg of protein). Treatment with com-
pounds significantly restored the SOD levels. 
Similarly, standards quercetin and pioglita-
zone significantly increased SOD levels to 
near normal values (Figure 8D). 
Catalase: FD significantly decreased liv-
er catalase levels by about 3 folds (12.83 ± 
3.6 U/mg vs 35.35 ± 3.6 U/mg of protein). 
However, treatment with test compounds 
increased the catalase levels compared to the 
FD-rats. Standards quercetin and pioglita-
zone significantly increased catalase levels to 
near normal values (Figure 8E). 
GST: The normal basal level of GST in 
NPD-rats was 0.013 ± 0.002 U/mg of protein 
in liver. Fructose feeding showed significant-
ly decreased levels of GST by about 4 folds 
(0.0031 ± 0.0014 U/mg). However, treatment 
with test compounds restored the GST activi-
ty significantly compared to FD-rats. The 
standards quercetin and pioglitazone signifi-
cantly increased GST levels to the normal 
values (Figure 8F). 
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Liver glycogen: FD-rats showed signifi-
cantly decreased glycogen in liver (4.32 ± 
1.09 mg/g vs 13.21±1.41 mg/g of wet liver). 
However, treatment with test compounds 
significantly increased the liver glycogen 
content compared to that of FD-rats. Querce-
tin and pioglitazone showed significantly 
increased levels of liver glycogen to near 
normal values (Figure 9). 
Glucose uptake from hemi-diaphragm 
muscle: The hemi-diaphragms from rats fed 
with FD showed significant reduction in glu-
cose uptake in vitro (4.21 ± 1.25 vs 10.28 ± 
2.51 mg/g of wet tissue/ 30 min, in NPD-rat 
(Figure 10). In the presence of insulin 
(35 μIU/ml), hemi-diaphragms from FD-rats 
did not show significant increase in glucose 
uptake, indicating insulin resistance in skele-
tal muscles. The treatment with test com-
pounds, quercetin and pioglitazone signifi-
cantly improved in vitro glucose uptake by 
skeletal muscles both in the presence and 
absence of insulin. JY-2 and JY-1 treatment 
significantly increased in vitro skeletal mus-
cle glucose uptake in the presence of insulin 
(22.12 ± 2.51 mg/g of wet tissue/30 min) in-
dicating reversal of insulin resistance in FD-
rats. 
 
Groups Glycogen  
(mg/ g of wet liver) 
 
G1 13.2 ± 1.40 
G2   4.32 ± 1.09 a 
G3   12.3 ± 1.52 b 
G4   12.5 ± 1.32 b 
G5   11.7 ± 1.23 b 
G6   12.8 ± 1.42 b 
G7     9.52 ± 1.56 a,b 
G8     8.34 ± 1.43 a,b 
Figure 9: Effect of 3-hydroxyflavones on liver glycogen in FD-fed rats 
Values are in mg/g of wet liver; G1: Normal control; G2: FD-fed diabetic control; G3: Diabetic + pioglitazone 
(10 mg/kg/day, p.o.); G4: Diabetic + Quercetin (10 mg/kg/day, p.o.); G5: Diabetic + JY-1; G6: Diabetic + JY-2; G7: 
Diabetic + JY-3; G8: Diabetic + JY-4; (test compounds at optimized dose 80 mg/kg/day, p.o.); All values mean ± 
SEM (n=6); a: p < 0.05 treatment groups are compared to normal control (G1); b: p < 0.05 when treatment groups 
are compared to induced group (G2). 
 
 
Groups 
 
Glucose up-take  
(mg/g of tissue/30 min) 
Without  
Insulin 
With  
Insulin 
G1 10.28 ± 1.53 25.56 ± 2.51 
G2   4.21 ± 1.25 #   6.52 ± 1.72# 
G3   11.0 ± 1.31†   23.0 ± 1.56*† 
G4   10.0 ± 1.31†   22.0 ± 2.43*† 
G5   8.74 ± 2.51†   22.0 ± 1.91*† 
G6 10.02 ± 2.08†   23.7 ± 2.50*† 
G7   5.82 ± 1.71   12.9 ± 1.98*† 
G8   6.90 ± 2.08†   15.9 ± 2.09*† 
Figure 10: Effect of 3-hydroxyflavones on glucose uptake from isolated hemi-diaphragms of FD-fed rats 
The experiment was conducted on the hemi-diaphragm isolated from the respective groups and compared with 
insulin and without insulin (35 μIU/ml); G1: Normal control; G2: FD-fed diabetic control; G3: Diabetic + pioglita-
zone (10 mg/kg/day, p.o.); G4: Diabetic + Quercetin (10 mg/kg/day, p.o.); G5: Diabetic + JY-1; G6: Diabetic + JY-
2; G7: Diabetic + JY-3; G8: Diabetic + JY-4; (test compounds at optimized dose 80 mg/kg/day, p.o.); Values are 
mean ± SEM; All values mean ± SEM (n=6); (*: p < 0.05 compared to same group in presence of insulin;  
#: p < 0.05 compared to G1 in presence/absence of insulin; †: p < 0.05 compared to G2 in presence/absence of 
insulin). 
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Antioxidant activity of 3-hydroxyflavone 
analogues 
The results of antioxidant activities, ex-
pressed as IC50, with different free radicals 
are shown in Table 1. Among the 4 mole-
cules selected, JY-2 showed the greatest an-
tioxidant activity comparable to quercetin 
followed by JY-1, JY-4 and JY-3 in DPPH, 
ABTS and hydroxyl radical scavenging as-
say (Table 1). The Fe3+ induced lipid peroxi-
dation was inhibited by the test compounds 
at low concentrations and expressed as IC50. 
The decreasing order of inhibition of lipid 
peroxidation is JY2>JY1>JY4>JY3 (Table 1). 
Transition metals such as iron and copper 
can participate in FR to produce free radicals 
such as •OH, which cause oxidative DNA 
damage. •OH formed from FR attacks gua-
nosine residues, resulting in DNA strand 
break. Hydroxyl radical scavengers can pro-
tect DNA from such damages. All four com-
pounds selected have inhibited calf thymus 
DNA damage by FR at 100-200 µM (Figure 
11). Calf thymus DNA protection study is a 
qualitative assay for the antioxidant efficacy 
of the compounds, and this assay has more 
relevance for in vivo correlations. 
LPS-stimulation of RAW 264.7 cells 
generates intracellular NO and ROS. In the 
presence of test compounds (3-200 µM) the 
NO release is scavenged significantly (Table 
2). The 50 % inhibitory concentration (IC50) 
was comparable to the quercetin. L-NAME 
(a standard NOS inhibitor) at 50 µM inhibit-
ed NO by 15.46 ± 0.048 %. ROS can be de-
tected based on the oxidation of the cell-
permeable non-fluorescent probe DCFH-DA 
to yield the highly fluorescent DCF (Chen et 
al., 2010). DPI, inhibitor of NADPH-oxida-
se, is a known standard for ROS-inhibition. 
Test compounds inhibited ROS with an effi-
cacy comparable to that of quercetin. DPI 
(5 µM) showed 56.06 ± 19.75 % ROS-in-
hibition (Table 2). 
 
 
Figure 11: Calf thymus DNA protection by 3-hydro-
xyflavones 
Lane 1: Control DNA; Lane 2: JY-1 (200 M) and 
DNA; Lane 3: JY-2 (200 M) and DNA; Lane 4: JY-3 
(400 M) and DNA; Lane 5: JY-4 (400 M) and DNA; 
Lane 6: Fenton reaction (FR) induced DNA damage; 
Lane 7: JY-1 (100 M) + FR with DNA; Lane 8: JY-1 
(200 M) + FR with DNA; Lane 9: JY-2 (100 M) + FR 
with DNA; Lane 10: JY-2 (200 M) + FR with DNA; 
Lane 11: JY-3 (200 M) + FR with DNA; Lane 12: JY-3 
(400 M) + FR with DNA; Lane 13: JY-4 (200 M) + 
FR with DNA. 
 
 
 
Table 1: Comparison of the IC50 of 3-hydroxyflavones against various free radicals 
Compounds DPPH
• Scav-
enging (µM) 
ABTS• –
Scavenging 
(µM) 
•OH Scavenging 
(mM) 
Inhibition of Lipid  
Peroxidation (µM) 
Quercetin   10.53 ± 1.22     7.48 ± 0.95     1.81 ± 0.21     65.98 ± 7.15 
JY-1   35.04 ± 3.18   21.47 ± 2.57     3.70 ± 0.48   147.21 ± 12.34 
JY-2   18.40 ± 2.71   10.66 ± 1.27     2.50 ± 0.30     99.61 ± 7.99 
JY-3   66.63 ± 6.79   63.87 ± 5.66     7.55 ± 0.86   217.47 ± 16.23 
JY-4   58.73 ± 7.5   55.46 ± 4.02     8.69 ± 0.95   210.10 ± 12.52 
(Values are mean ± SEM; n=3) 
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Table 2: Inhibition of NO and ROS by 3-hydroxy-
flavones in LPS activated RAW cells 
Compounds 
IC50 (µM) 
Nitrite 
release 
inhibition 
ROS 
inhibition 
JY-1 42.63 ± 2.94 30.66 ± 8.32 
JY-2 30.89 ± 2.86 36.53 ± 2.72 
JY-3 38.04 ± 2.88 20.99 ± 7.20 
JY-4 10.39 ± 6.46 29.95 ± 17.63 
Quercetin 12.83 ± 10.00 26.19 ± 1.00 
(Values are mean ± SEM of two independent experi-
ments). In the assays cells were stimulated with 
10 μg/ml LPS and treated with increasing concentra-
tions of test compounds (3-200 µM). Concentrations of 
NO2- in the medium were determined by the Griess 
assay. Intracellular concentration of ROS was deter-
mined by fluorometric assay using DCFH-DA. % inhi-
bition of NO and ROS production was calculated 
against untreated stimulated cells (positive control) 
that were not treated but were stimulated with LPS 
and contained 0.1 % DMSO. L-NAME (50 µM), in ni-
trite release assay showed 15.46 ± 0.048 % inhibition 
and an IC50 of 104.17 ± 5.48 µM; DPI (5 µM) showed 
73.12 ± 1.41 % inhibition of NO-release and 56.06 ± 
19.75 % inhibition of ROS. 
 
Antiglycation activity of 3-hydroxyflavone 
analogues 
The antiglycation activity is expressed as 
IC50 as shown in Table 3. In the early stage 
glycosylation (Hb-glucose assay), test com-
pounds showed higher IC50 compared to the 
middle stage and late stage AGEs formation 
(BSA-MGO and BSA-Glucose assays re-
spectively). Results of the antiglycation po-
tency, as measured by Hb-glucose assay, is 
in the decreasing order of JY-2>JY-1>JY-
3>JY-4. Test compounds showed equal po-
tencies in the middle stage and late stage 
glycation assays. Overall, the order of poten-
cy of newly synthesized compounds is JY-
2>JY-1>JY-3>JY-4. JY-2 showed the max-
imum potency in all the stages of glycation 
assays which was comparable to the stand-
ards quercetin and aminoguanidine (Table 
3). 
 
Glucose uptake from L6 myotubes by  
3-hydroxyflavone analogues  
In the presence of test compounds the 
glucose uptake by L6 myotubes was en-
hanced significantly. There was no signifi-
cant difference between glucose uptake in-
duced by test compounds and standard quer-
cetin (p>0.05) indicating that the test com-
pounds were comparable to quercetin in en-
hancing the glucose uptake in vitro. The test 
compounds showed a dose-dependent in-
crease in glucose uptake and were relatively 
more potent than quercetin with reference to 
the individual EC50 values. The test com-
pound JY-4 showed highest activity fol-
lowed by JY-3, JY-2 and JY-1 (Figure 12). 
 
Figure 12: Effect of 3-hydroxyflavones on glucose 
uptake by L6 myotube 
Graph represents effective concentration (EC50) of 3-
hydroxyflavone analogues for percentage increase in 
glucose uptake by L6 myotube with respect to untreat-
ed control; Quercetin was used as standard flavonoid 
for comparison; Insulin (100 nM) increased basal glu-
cose uptake by 222.40 ± 4.20 % was used as stand-
ard; Data expressed as mean ± SEM. 
 
 
Table 3: In vitro antiglycation activity of 3-hydroxyflavones using quercetin and aminoguanidine as 
positive control 
Compounds 
IC50 (µM)a 
Hb-glucose assay BSA-MGO assay BSA-glucose as-say 
 
 
Fructosamine  
assay 
AGb       7.62 ± 0.57       4.91 ± 0.43       4.82 ± 0.38       5.54 ± 0.36 
Quercetin     98.67 ± 7.40     65.70 ± 4.26     59.65 ± 3.59     61.73 ± 4.01 
JY-1   147.61 ± 11.07   127.18 ± 7.80   140.02 ± 8.40   140.52 ± 9.83 
JY-2   114.13 ± 8.55     99.48 ± 5.96     99.94 ± 4.92     99.21 ± 6.44 
JY-3   210.13 ± 13.65   223.98 ± 10.67   219.01 ± 16.25   204.20 ± 12.25 
JY-4   218.00 ± 15.26   229.26 ± 12.04   196.05 ± 13.78   219.65 ± 14.27 
AG: Aminoguanidine; a: All values are Mean ± SEM; b: IC50 concentration of AG was expressed as mM 
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DISCUSSION 
The increased consumption of fructose 
has been proposed as the cause of increased 
incidence of diabetes and metabolic syn-
drome in human population (Johnson et al., 
2007). In humans, high fructose diets induce 
dyslipidemia and modulate intracellular lipid 
deposition (ectopic lipids) which is nothing 
but the deposition of triglyceride in cyto-
plasm of non-adipose cells, such as hepato-
cytes, muscle fibers, or endocrine cells. Such 
ectopic lipid deposition in the liver and skel-
etal muscle is closely linked to tissue-
specific insulin resistance (Hyakukoku et al., 
2003). In addition, fructose may impair en-
dothelial function through increased creati-
nine and uric acid production (Le et al., 
2009; Tappy and Le, 2010). 
It is a well-known fact that fructose feed-
ing in rats increases TG levels, leading to 
insulin resistance as well as obesity (Patel et 
al., 2009). In our study we found that body 
weight of rats increased significantly after 6 
weeks of high fructose feeding, while basal 
body weights correlated with total food in-
take (Figure 3). However, test compounds 
did not increase the body weight of FD-rats 
when compared to controls. JY-2 and JY-1 
significantly inhibited body weight gain with 
an efficacy comparable to that of pioglita-
zone and quercetin. The observation made 
here was that the decrease in body weight is 
mainly because of decrease in food intake, 
which may be due to combined effect of ap-
petite suppression, hypoglycemic and hypo-
lipidemic activity. 
It was also observed that TGs were ele-
vated in FD-rats. Test compounds, particu-
larly JY-2, restored dyslipidemic markers to 
near-normal values in FD-rats. Dietary fruc-
tose has been shown to increase ectopic fat 
deposition in tissues and its normalization in 
FD-rats could have been at least partly medi-
ated by the anti-lipodystropic action of test 
compounds. Further, test compounds could 
bring down elevated insulin levels and 
HOMA-IR, a biomarker for insulin re-
sistance (Matthews et al., 1985). The in-
creased lipid levels in FD-rats possibly could 
have resulted in the increase of serum insu-
lin, HOMA-IR and FBG (Figure 4 and 5). In 
other words, FD-rat model combines the 
symptoms of hyperglycemia, dyslipidemia 
and hyperinsulinemia in the same animal. 
JY-2 and JY-1 were found to normalize all 
three parameters in fructose-fed rats. Further, 
JY-2 and JY-1 significantly increased the 
insulin induced glucose clearance (K-ITT) in 
the same experimental model. 
High fructose feeding in rats mimics 
many of the symptoms of type 2 diabetes 
(T2D) in humans, especially insulin re-
sistance, glucose intolerance, dyslipidemia 
and renal impairment. Despite several limita-
tions, the FD-rat model may be useful to de-
fine potential treatments for T2D or the me-
tabolic syndrome (Patel et al., 2009). Simi-
larly, high fructose consumption induces ox-
idative stress, which is a cause for the meta-
bolic complications of diabetes (Delbosc et 
al., 2005). In our study, we found that the 
antioxidant defense in liver was significantly 
impaired in FD-rats. The levels of TBARS 
increased and that of total thiols, GSH, cata-
lase, SOD and GST decreased in FD-rats. 
Treatment with JY-2, JY-1 quercetin and 
pioglitazone significantly restored the anti-
oxidant defense (Figure 8). 
High fructose feeding decreases insulin-
induced insulin receptor substrates (IRS-1/2) 
phosphorylation in both the liver and muscle 
in rats (Tappy and Le, 2010). This, in turn, 
will lead to polyol formation and AGEs, 
which can contribute to the numerous com-
plications seen in diabetes. Further, oxidative 
stress due to chronic hyperglycemia is a 
well-known cause for plasma and tissue pro-
tein glycation. Glycation-induced hemoglo-
bin modifications (HbA1c) due to hypergly-
cemia are known to cause further oxidative 
stress via iron-dependent free radical reac-
tions. Furthermore, the increased AGEs in 
the plasma are associated with increased se-
rum creatinine. Our findings were in accord-
ance with earlier findings in the literature 
(Yanagisawa et al., 1998). The serum AGEs 
and creatinine increased significantly in FD-
rats and treatment with the antioxidant mole-
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cule JY-1 and JY-2 normalized these elevat-
ed levels supporting the alleviation of oxida-
tive stress. JY-1 and JY-2 were almost as 
efficacious as quercetin and pioglitazone in 
lowering elevated serum AGEs and creati-
nine. 
Fructose diet induces depletion of glyco-
gen, chiefly in liver, resulting from de-
creased activity of glycogen synthase, gluco-
kinase activity or down-regulation of gene 
expression for these enzymes owing to insu-
lin resistance (Tappy and Le, 2010). Thus, 
chronic fructose diet leads to increased ef-
flux of glucose. Decreased liver glycogen in 
FD-rats supports earlier reports from the lit-
erature. Treatment with JY-1 and JY-2 sig-
nificantly normalized glycogen levels in the 
liver. JY-2 and JY-1 treatment also increased 
liver glycogen by three-fold compared to 
FD-rats, which is comparable to that of quer-
cetin and pioglitazone. 
ROS are believed to play a causal role in 
multiple forms of insulin resistance (Houstis 
et al., 2006). Oxidative stress is one among 
the major factors that leads to several diabe-
tes-related metabolic complications such as 
nephropathy, retinopathy and all types of 
neuropathies, and antioxidants are found to 
be beneficial (Calcutt et al., 2009). The test 
compounds selected for the study have 
shown good in vitro antioxidant activity. In 
these compounds 3-OH group is contributing 
to antioxidant activity. JY-2 has an addition-
al 7-OH group which might be contributing 
to the higher antioxidant activity. Also, the 
C-ring, rather than B-ring of flavone is con-
tributing more to its’ DPPH radical scaveng-
ing activity (Tsimogiannis and Oreopoulou, 
2006). Hence, modification of γ-benzo-
pyrone ring in flavones could yield better 
antioxidant molecules. JY-1 and JY-2 pos-
sess -N,N-dimethylamino group, which 
could have enhanced the antioxidant activity 
of these flavones.  
Hydroxyl radical is the most deleterious 
oxidizing radical among those present in dis-
ease pathophysiology and reacts instantane-
ously with important molecules such as 
DNA and membrane lipids. In the assay sys-
tem, •OH radical is generated by a mixture of 
ascorbic acid, H2O2 and ferric-EDTA. The 
•OH attacks deoxyribose, and initiates a cas-
cade of reactions leading to fragmentation. 
One of the fragments generated is malon-
dialdehyde (MDA). MDA reacts with thio-
barbituric acid (TBA) at low pH, which upon 
heating will give a pink chromogen (adduct 
of TBA and MDA) (Cheeseman et al., 1988). 
In the presence of test compounds, low ab-
sorption values indicate the protection of de-
oxyribose from •OH. 
Though the test compounds have good in 
vitro radical scavenging activity, this cannot 
be concluded for their therapeutic applica-
tions, because these in vitro assays are done 
in non-physiological pH values and hence, it 
is impossible to extrapolate the results to 
physiological environment. The proof of bio-
efficacy must emanate from application of 
reliable in vivo models where markers of 
baseline oxidative damage are examined 
from the standpoint of how they are affected 
by changes in diet or endogenous antioxidant 
defense. In this view the inhibition of lipid 
peroxidation and DNA protection assays will 
have greater impetus and greater biological 
relevance than DPPH, ABTS•− and •OH 
scavenging activity (Huang et al., 2005).  
Inhibition of lipid peroxidation is also an 
indicator of O2•- and lipid radical inhibition 
activity. Lipid peroxidation is initiated by 
abstraction of a hydrogen atom from bis-
allylic methylene carbon positioned on a 
polyunsaturated side chain of a lipid mole-
cule. These carbons are attacked preferential-
ly over the secondary -C-H bonds because of 
the production of a resonance-stabilized car-
bon-centered radical. As the name peroxida-
tion indicates, the auto-reaction initiation 
follows the carbon radical to be stabilized by 
a molecular rearrangement to form a conju-
gated diene. Further, a variety of propagation 
reactions may take place. The most likely 
reaction that takes place is between lipid rad-
ical and oxygen. After the addition of mo-
lecular oxygen to the lipid radicals, which is 
very fast in aerobic environment, the result-
ing peroxyl radical can attack neighboring 
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polyunsaturated fatty acids or undergo in-
tramolecular cyclization followed by break-
down to compounds such as, ethane, n-
pentane and MDA (Huang et al., 2005). We 
followed ferrous sulfate stimulated lipid per-
oxidation in the rat brain homogenate result-
ing in the formation of MDA. In the pres-
ence of antioxidants, formation of this 
MDA-TBA chromogen is reduced, which is 
expressed as antioxidant activity. 
Natural flavonoids, at low concentrations 
have shown prevention of DNA damage 
whereas high concentrations (above 100 µM) 
have shown to induce DNA-damage and this 
was attributed to increase in the number 
of -OH groups present in flavonoids. Our 
investigational compounds have minimum 
number of OH group and could have higher 
safety in preventing DNA damage. 
RAW 264.7 cells are murine macrophag-
es generally used for determination of intra-
cellular ROS which are obligatory mediators, 
generated via the activation of NADPH-
oxidase and other LPS signaling. NO is a 
highly reactive molecule and inducible nitric 
oxide synthase (iNOS) catalyses the reaction 
leading to increased RNS in inflammatory 
conditions. LPS induces vascular contractile 
and energetic failure by both exogenous and 
endogenous NO and ONOO- in pathogenesis 
of endotoxic shock (Szabo et al., 1996). In 
diabetes the chronic increase-ROS associated 
ONOO- production has similar consequences 
of micro- and macrovascular complications 
(Son, 2012). Many natural flavonoids stud-
ied for inhibition of NO in RAW 264.7 cells, 
is reported to down-regulate gene transcrip-
tion rather than directly inhibiting iNOS. 
Some flavonoids target nuclear factor kappa 
B (NFκB) gene expression and interferon 
(IFN-γ) induced NFκB transactivation. The 
investigational molecules were potent NO 
release inhibitors and the IC50 values were 
comparable to the standard natural flavones. 
The antiglycation activities of flavonoids 
have been reviewed by experts elsewhere 
(Matsuda et al., 2003). However, this theory 
has several limitations because (1) only one 
type of assay (BSA-glucose method) was 
used to compare flavonoids (2) only natural 
flavonoids are considered. In the present 
work, we have determined the early stage 
(Amadori products) middle stage (RCS) and 
last stage (AGEs formation and cross-
linking) glycoxidation and its inhibition by 
test compounds. 
The phenomenon of protein glycation 
was demonstrated in the reaction mixtures of 
protein with glucose by several model sys-
tems in vitro. Glucose and dicarbonyl com-
pound (such as MGO) are used as glycation 
agents, which are commonly adopted for the 
antiglycation studies. Hemoglobin and BSA, 
used as amine sources, serve as targets for 
glycation agent (Wu and Yen, 2005). In the 
initial stage, glucose reacts with an amine 
group to form a labile Schiff base that rear-
ranges to the Amadori product. The Schiff 
base is highly prone to oxidation and free 
radical generation, which leads to the for-
mation of RCS such as glyoxal. BSA-
glucose assay is the last stage glycosylation 
assay, where some amount of intermediate 
Amadori products remains unreacted are de-
termined by fructosamine assay (Sharma et 
al., 2002).  
Increased glycation and build-up of tis-
sue AGEs have been implicated in diabetic 
complications because they can alter enzy-
matic activity, decrease ligand binding, mod-
ify protein half-life and alter immunogenici-
ty, which in turn play a role in atherogenesis. 
Glycation-derived free radicals can cause 
protein fragmentation and oxidation of nu-
cleic acids and lipids. The oxidized lipids 
enhance the inflammatory condition and are 
called as advanced lipoxidation end-products 
(ALEs) (Thorpe and Baynes, 2003). The 
amino groups of adenine and guanine bases 
in DNA are also susceptible to glycation and 
AGEs formation, probably by reactive intra-
cellular sugars. AGEs could also form on 
phospholipids and induce lipid peroxidation 
by a direct reaction between glucose and 
amino groups on phospholipids such as 
phosphatidyl ethanolamine and phosphati-
dylserine residues (Ahmed, 2005). Given the 
link mentioned above between glycation and 
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oxidation, we hypothesized that antioxidant 
flavones might possess antiglycoxidative ac-
tivities. Many data have shown that typical 
antioxidants/nutrients such as vitamin B1 
(thiamine pyrophosphate), B6 (pyridoxa-
mine), C, E, niacinamide, carnosine, and so-
dium selenite inhibited the in vivo and in 
vitro AGEs formation (Ahmed, 2005; Reddy 
and Beyaz, 2006). Similarly, compounds 
such as aminoguanidine, carnosine, homo-
carnosine, aspirin, metformin OPB-9195, 
phenacylthiazolium bromide derivatives are 
found to be effective antiglycation molecules 
(Reddy and Beyaz, 2006). Our studies 
demonstrated that the synthetic 3-hydroxy-
flavones having antioxidant activity will in-
hibit the protein glycation effectively and 
significantly both in vitro and in vivo and are 
comparable to that of standard flavonoid 
quercetin. 
Test compounds enhanced glucose up-
take in L6 myotubes indicating that they 
have an insulinomimetic activity on muscle 
cells. Such type of observation has also been 
reported for natural flavonoids (Zygmunt et 
al., 2010). Hence the test compounds might 
have the ability to modulate glucose trans-
porter (GLUT-4) in skeletal muscle cells. It 
was noted that the test compounds are more 
potent than quercetin and among the test 
compounds JY-4 was most potent in enhanc-
ing the glucose uptake. These finding were 
also supported by glucose uptake by insulin-
resistant isolated hemi-diaphragm of FD-fed 
rats. These findings are in accordance with 
published reports which say that fructose in-
take reduces GLUT4 translocation in the 
skeletal muscle, leading to a drastic decrease 
in glucose uptake (Shih et al., 2009). Insulin-
mediated (35 μIU/ml) glucose uptake in 
hemi-diaphragm was significantly increased 
in the treated groups, but not in untreated 
FD-rats. 
 
CONCLUSION 
The test molecules are novel synthetic 
leads (JY-1, JY-2, JY-3 and JY-4) that could 
potentially alleviate insulin resistance and 
reduce hyperglycemia, dyslipidemia and in-
crease in vivo antioxidant defense in high-
fructose fed insulin resistant rats. These 
compounds enhanced glucose uptake by L6 
myotubes to a greater extent than quercetin. 
Although we have not been able to conclu-
sively establish the precise mechanism of 
action of this molecule, it is possibly related 
to the potent in vivo antioxidant activity of 
this molecule. Free radical scavenging activi-
ty of JY-1, JY-2 JY-3 and JY-4 can be at-
tributed to their ability to donate hydrogen, 
donate/accept electron, quenching of •OH, 
protection of DNA from Fenton-reagent in-
duced damage and inhibition of lipid peroxi-
dation. Further, NO-scavenging and ROS-
inhibition in RAW 264.7 cells is suggestive 
of a preventive mechanism in diabetic vascu-
lar complications. The good antiglycation 
activity of test compounds (both in vitro and 
in vivo) can be attributed to their high antiox-
idant activity. Thus, results suggest that these 
synthetic flavones could be playing a role 
either in modulating glucose uptake in liver 
and skeletal muscles or in stimulating insulin 
action. Above conjectures warrants further 
study on mechanism of action of test com-
pounds. 
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